Last reviewed · How we verify
topical pimecrolimus treatment
Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.
Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin. Used for Atopic dermatitis (eczema), Allergic contact dermatitis, Seborrheic dermatitis.
At a glance
| Generic name | topical pimecrolimus treatment |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | Calcineurin inhibitor (topical immunosuppressant) |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Pimecrolimus binds to calcineurin and prevents its interaction with NFAT (nuclear factor of activated T cells), thereby blocking T-cell proliferation and the release of pro-inflammatory mediators. When applied topically, it reduces skin inflammation without the systemic immunosuppression associated with oral calcineurin inhibitors, making it suitable for localized inflammatory skin conditions.
Approved indications
- Atopic dermatitis (eczema)
- Allergic contact dermatitis
- Seborrheic dermatitis
Common side effects
- Application site burning or irritation
- Pruritus at application site
- Skin infections (secondary bacterial or viral)
- Headache
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (PHASE3)
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (NA)
- Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) (PHASE4)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis (PHASE3)
- Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba (PHASE2, PHASE3)
- 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX (PHASE2)
- Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- topical pimecrolimus treatment CI brief — competitive landscape report
- topical pimecrolimus treatment updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI